
Smart Photodynamic Therapy for Acne by Reversibly Switchable Intersystem Crossing in Pure Organic MaterialsAward last edited on: 4/12/2023
Sponsored Program
SBIRAwarding Agency
NIH : NIAMSTotal Award Amount
$258,600Award Phase
1Solicitation Topic Code
846Principal Investigator
Dalar BansalCompany Information
Advanced Cytometry Instrumentation Systems
Baird Research Park 1576 Sweet Home Road
Amherst, NY 14228
Amherst, NY 14228
(716) 689-9797 |
information@acisflowcyte.com |
www.acisflowcyte.com |
Location: Single
Congr. District: 26
County: Erie
Congr. District: 26
County: Erie
Phase I
Contract Number: 1R43AR079947-01A1Start Date: 9/22/2022 Completed: 8/31/2023
Phase I year
2022Phase I Amount
$258,600Public Health Relevance Statement:
Narrative - ACIS, LLC proposes a new approach to treat moderate to severe acne by a novel photodynamic therapy application which alleviates the common photodynamic therapy limitations via reversible on/off switching of intersystem crossing in small organic molecules, thereby boosting (in "on" mode) or suppressing (in "off" mode) singlet oxygen production. The proposed PDT modality is called "Smart PDT" or "Spot PDT" (S-PDT) because it is activated in sebaceous glands only and it will not affect the surrounding healthy tissue. This treatment offers unprecedented precision and resolves the general limitations of current photodynamic therapy.
Project Terms:
absorption, Acne Vulgaris, Adult, 21+ years old, Adult Human, adulthood, Affect, Antibiotics, Antibiotic Agents, Antibiotic Drugs, Miscellaneous Antibiotic, Bacteria, Bacterial Infections, bacteria infection, bacterial disease, Biopsy, Malignant Neoplasms, Cancers, Malignant Tumor, malignancy, neoplasm/cancer, Cell Culture Techniques, cell culture, cell cultures, Cell Line, CellLine, Strains Cell Lines, cultured cell line, Cells, Cell Body, Cytoplasm, Dermatology, Dermis, Corium, Cutis, Pharmaceutical Preparations, Drugs, Medication, Pharmaceutic Preparations, drug/agent, Environment, Epidermis, Female, Fibroblasts, Human, Modern Man, In Vitro, Inflammation, Isoelectric Point, Lead, Pb element, heavy metal Pb, heavy metal lead, Light, Photoradiation, Lipids, Molecular Conformation, Molecular Configuration, Molecular Stereochemistry, conformation, conformational state, Persons, Eye Socket, Orbit, Orbital Cavity, Ocular orbit, Production, Retinoic Acid Agent, Retinoic Acid and Derivatives, Retinoids, Risk, Sebaceous Glands, Sebums, Sebum, salt, Sodium Chloride, Solubility, Specificity, Spinal Column, Spine, backbone, Vertebral column, Staining method, Stains, Testing, Tissues, Body Tissues, Triplet Multiple Birth, Triplets, United States, Woman, nile red, Singlet Oxygen, Singlet Dioxygen, Measures, Photosensitizing Agents, Photosensitizers, photosensitizer, base, dosage, Site, Area, Surface, Chronic, Microscopic, Penetration, Phase, Medical, psychologic, psychological, Series, Adolescent, Adolescent Youth, juvenile, juvenile human, Chemicals, Chemical Structure, Lesion, Epithelial, uptake, Endocrine Therapy, Hormonal Therapy, hormone therapy, Spottings, Exposure to, Inflammatory, Frequencies, Dependence, Oral, cell type, System, American, Lytotoxicity, cytotoxicity, triplet state, Molecular Modeling Nucleic Acid Biochemistry, Molecular Modeling Protein/Amino Acid Biochemistry, Molecular Models, molecular modeling, Structure, novel, healthcare economics, health care economics, Topical Drug Administration, administer topically, apply topically, deliver topically, topical administration, topical delivery, topical drug application, topical treatment, topically administered, topically applied, topically delivered, topically treated, treat topically, Topical application, Duct, Duct (organ) structure, Modality, Acne, PUVA, Photochemotherapy, Photodynamic Therapy, neoplasm/cancer photoradiation therapy, PUVA Photochemotherapy, Modeling, Adverse effects, Skin, Gland, Acidity, Address, cytotoxic, Data, Clinical Treatment, trial regimen, trial treatment, Validation, Characteristics, Molecular, Process, Therapeutic Effect, Development, developmental, care burden, design, designing, next generation, novel strategies, new approaches, novel approaches, novel strategy, Treatment Efficacy, intervention efficacy, therapeutic efficacy, therapy efficacy, Population, Coupling, prototype, side effect, skin damage, cutaneous damage, dermal damage
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00